How tirzepatide dosing works: a practical guide to the schedule

Your first pen arrives: what the 2.5 mg dose is actually doing

Picture it: the pen is in the fridge, instructions read twice, and you're expecting to feel something happen quickly. The 2.5 mg starting dose will probably disappoint those expectations, and that's by design. This opening phase exists almost entirely to settle your digestive system before you reach any dose that meaningfully reduces appetite. Nausea, bloating and loose stools are the most commonly reported early effects when tirzepatide is started; beginning at the lowest strength keeps those effects manageable for most people.

After four weeks at 2.5 mg, the standard next step is 5 mg, the point where the active weight-management effect typically begins. The tirzepatide overview explains the dual GIP and GLP-1 receptor mechanism that drives this: slowing gastric emptying and signalling satiety through two separate gut-hormone pathways. Understanding that the 2.5 mg pen is preparation, not treatment, helps explain why patience matters most in those first weeks, and if you want a thorough breakdown of how the medicine works from the ground up, our tirzepatide guide covers everything from mechanism to what to expect across the schedule. As the NHS medicines page on tirzepatide describes, the medicine is titrated gradually to reduce side-effect risk.

One quick checking habit worth building: before you inject each week, glance at the strength printed on the pen label and confirm it matches what your prescriber has recorded for your current dose, and if you want a clear reference while doing so, our tirzepatide dosing page sets out every strength and step in one place. It takes under a minute and catches any dispensing confusion early.

Moving through the schedule: what drives each dose increase

The six strengths from 2.5 mg to 15 mg are not a race to be completed. They are a structured ladder your prescriber climbs with you, and the pace is governed by two things: tolerability and clinical response. Most people step up every four weeks, but if side effects are still noticeable and disruptive at a given dose, staying there longer is a legitimate clinical decision, not a setback.

You will not be increased to the next dose automatically. At nume, a prescriber personally reviews your situation before every repeat order; there is no algorithm deciding your next step. If you are thinking about how Mounjaro dose increases are handled in practice, that page covers what evidence a prescriber looks at before moving you up. Evidence of your current weight and recent tolerance is part of that review, the same clinical rigour that applies at the start continues throughout.

The NICE appraisal of tirzepatide (NICE TA1026) sets a clear benchmark: if a patient has not lost at least 5% of their starting body weight after six months at the highest dose they can tolerate, continuing treatment should be reviewed. This is a clinical checkpoint built into licensed use, not a failure, but a signal to reassess the approach.

The upper end of the schedule and what the trial data shows

The 15 mg dose is the ceiling, and trial evidence suggests it carries the strongest average effect. In the SURMOUNT-1 study (2,539 adults with obesity, 72 weeks), participants on 15 mg achieved an average body-weight reduction of around 20–21%, with some analyses reaching higher. The SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, found tirzepatide produced greater average weight loss than semaglutide 2.4 mg over the same period.

Not everyone reaches 15 mg. Some people find an earlier dose delivers strong results with better tolerability, and their prescriber may judge that moving further brings diminishing benefit at higher side-effect burden. Our Mounjaro guide covers the full clinical picture, including what the evidence base shows across the dose range and how prescribers weigh up individual responses. The key message from the trials is that meaningful outcomes appear well before the maximum, and the schedule is there to find each person's optimal point, not to push everyone to the top.

Cost is a practical part of the picture too. Higher doses carry higher list prices, and understanding what the full treatment cost covers (including consultation, prescription, and aftercare) helps set realistic expectations before you start.

What the schedule cannot tell you: the clinical judgement piece

A dosing schedule is a framework, not a prescription in itself. Tirzepatide is a prescription-only medicine, and the schedule your prescriber sets will reflect details a printed guide cannot account for: other medicines you take, conditions that affect how the drug is tolerated, your weight trajectory and how you are actually feeling week to week. The interaction with oral contraceptives is one concrete example: because tirzepatide slows gastric emptying, pill absorption may be reduced, and current NHS guidance recommends adding a non-oral method of contraception for the first four weeks of treatment and for four weeks after each dose increase. Your prescriber will flag this during your consultation.

If you have questions about your current dose, a missed injection, or whether a side effect warrants pausing treatment, those decisions belong with your prescriber and the Patient Information Leaflet, not a general guide. Our frequently asked questions cover some of the most common concerns, and the clinical team is reachable through aftercare support seven days a week. For a broader picture of how tirzepatide sits within weight management options, the weight-loss treatment overview is a useful starting point, and if you want to understand how peptide formulations are used you can find specific guidance on tirzepatide peptide dosing in our dedicated section. If you are ready to discuss whether tirzepatide is right for you and what schedule your prescriber would propose, you can speak to our prescribers through a free consultation.